Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical CoSTU:ON4 -1.68%89 EV-to-OCF is 7.63 as of Sep. 08, 2026, which is 51% below its 10-year median of 15.67. GuruFocus rates STU:ON4 with a GF Score™ of 89/100 and a GF Value™ of €11.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 57.4% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ono Pharmaceutical Co's Enterprise Value is €5,724 Mil.
Ono Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €750 Mil. Therefore, Ono Pharmaceutical Co's EV-to-OCF for today is 7.63.
The historical rank and industry rank for Ono Pharmaceutical Co's EV-to-OCF or its related term are showing as below:
STU:ON4'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.74 Med: 15.67 Max: 103.13
Current: 7.72
During the past 13 years, the highest EV-to-OCF of Ono Pharmaceutical Co was 103.13. The lowest was 6.74. And the median was 15.67.
STU:ON4's EV-to-OCF is ranked better than 57.4% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.53
vs STU:ON4: 7.72
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ono Pharmaceutical Co (STU:ON4) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ono Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Ono Pharmaceutical Co's share price for today is €13.175.
Ono Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.897.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's EV-to-OCF falls into.
Ono Pharmaceutical Co's current Enterprise Value is €5,724 Mil.
Ono Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €750 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co (STU:ON4) has a EV-to-OCF of 7.63 as of Sep. 08, 2026. This is 51% below median its historical median of 15.67. Over the past decade, Ono Pharmaceutical Co's EV-to-OCF has ranged from 6.74 to 103.13. According to the industry distribution chart, Ono Pharmaceutical Co ranks #429 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 42.6%.
Is Ono Pharmaceutical Co's EV-to-OCF too high?
Ono Pharmaceutical Co's current EV-to-OCF of 7.63 is 51% below median its 10-year median of 15.67. Over the past 10 years, this metric has ranged from a low of 6.74 to a high of 103.13. The Drug Manufacturers industry median EV-to-OCF is 10.53. Ono Pharmaceutical Co's value of 7.63 is 27.5% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #429 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #429 out of 1007 companies for EV-to-OCF. This puts Ono Pharmaceutical Co in the upper half of its industry. The industry median EV-to-OCF is 10.53. Ono Pharmaceutical Co's value of 7.63 is 27.5% below this benchmark. Historically, Ono Pharmaceutical Co's own EV-to-OCF has ranged from 6.74 to 103.13 over the past decade. While the company's 10-year median is 15.67 vs. the industry median of 10.53, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current EV-to-OCF of 7.63 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current EV-to-OCF is 7.63, which is 51% below median its own 10-year median of 15.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (STU:ON4) is currently considered Modestly Overvalued. The stock's GF Value™ is €11.73, compared to a current price of €13.18 — trading 12.3% above its estimated fair value. The current EV-to-OCF is 7.63, which is 51% below median its 10-year median of 15.67 and 27.5% below the Drug Manufacturers industry median of 10.53. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ono Pharmaceutical Co (STU:ON4), the current EV-to-OCF is 7.63 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (STU:ON4) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of €13.18 is trading 12.3% above its estimated GF Value™ of €11.73.
GuruFocus considers Ono Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for STU:ON4:
EV-to-OCF: 7.63 (51% below median its 10-year median of 15.67)
GF Value™: €11.73 vs. price of €13.18 (12.3% above fair value)
Industry Position: 27.5% below the Drug Manufacturers median (#429 of 1007)
No single metric tells the full story. See the STU:ON4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score
Get the complete analysis for STU:ON4
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ON4 has been successfully added to your 
